Novo Nordisk's shares rose by more than 16% on Tuesday, as the results of the trial exceeded investor expectations. The weight-loss drug Wegovy lowers the risk of 'adverse cardiovascular events' by 20%, according to data from a major trial shared by the drug's maker Novo Nordisk Tuesday, causing the company's shares to surge.
The weight-loss drug Wegovy lowers the risk of “adverse cardiovascular events” by 20%, according to data from a major trial shared by the drug’s maker Novo Nordisk Tuesday, causing the company’s shares to surge.... [+]press release
, Novo Nordisk said that a weekly 2.4 milligram dose of semaglutide—the generic name for Wegovy, which is also sold under the name “Ozempic”—resulted in a 20% reduction in heart attacks and strokes. The trial measured data over a period of five years and involved 17,604 participants aged 45 or older who were either overweight or obese.
The trial also found that the 2.4 mg dosage was “safe and well-tolerated” in line with previous similar trials. The announcement of the trial results caused the drug maker’s Copenhagen-listed shares to surge by more than 16% on Tuesday, before settling at around 13.4% in the green during afternoon trading.This is a developing story.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Novo's weight-loss drug Wegovy cuts risk of heart disease by 20% - trial dataNovo Nordisk's obesity drug Wegovy has shown a clear medical benefit, reducing the risk of heart disease by 20% according to a large late-stage study. The positive results have boosted the Danish drugmaker's hopes of repositioning Wegovy as more than just a lifestyle drug.
Weiterlesen »
Psychiatrists Prescribe Wegovy for Medication-Induced Weight GainPsychiatrists are increasingly prescribing the popular weight-loss drug Wegovy to patients who gain weight from medicines used to treat mental disorders, such as schizophrenia or bipolar disorder.
Weiterlesen »
3 Reasons Why Shiba Inu (SHIB) Saw Massive 20% BreakthroughWith imminent launch of Shibarium, oversold market and investor confidence in face of scams, Shiba Inu (SHIB) saw significant 20% surge
Weiterlesen »
Monthly costs for homebuyers rise nearly 20%The average rate on 30-year fixed mortgage rose to 6.9% this week.
Weiterlesen »
The Top 20 Most-Followed Male K-Pop Idols On Instagram in 2023 | allkpopInstagram has become a go-to destination for K-Pop enthusiasts to stay updated on their favorite idols' day-to-day lives.K-pop idols use their perso…
Weiterlesen »